Oncopeptides AB (ONCO) AI Stock Analysis

• Market Cap: kr321.97M
• Dividend Yield: N/A
• Average Volume (3M): 604.51K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: 1.72%
• EPS Growth: 32.54%
• Country: SE
• Employees: 80
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 211,263,900
• 10 Day Avg. Volume: 981,960
• 30 Day Avg. Volume: 604,513
• PEG Ratio: -0.06
• Price to Book (P/B): 7.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: kr1.50 ▼(-1.32%Downside)

The overall stock score is negatively impacted by weak financial performance, unfavorable valuation, and bearish technical indicators. The company's persistent losses, high leverage, and cash flow challenges, combined with negative market momentum, have led to a low stock score. While the strong cash position is a positive factor, it is outweighed by the financial and market challenges.

Oncopeptides AB Business Overview & Revenue Model

Company Description

Oncopeptides AB is a Sweden-based pharmaceutical company that focuses on the development of therapies for difficult-to-treat hematological diseases. The company's core product is melflufen (INN melphalan flufenamide), a peptide-drug conjugate intended for the treatment of multiple myeloma, which is a type of blood cancer. Oncopeptides leverages its proprietary Peptide-Drug Conjugate technology to deliver targeted treatments that improve the lives of patients with rare and hard-to-treat disorders.

How the Company Makes Money

Oncopeptides AB primarily generates revenue through the commercialization of its pharmaceutical products, particularly melflufen. As a biotechnology company, its revenue model relies heavily on the successful development, approval, and marketing of its drug candidates. The company engages in partnerships and collaborations with other pharmaceutical entities to enhance its research and development capabilities, expand its market reach, and secure funding. Additionally, Oncopeptides may earn revenue through licensing agreements and milestone payments from these collaborations. The company's financial performance is significantly influenced by regulatory approvals, clinical trial outcomes, and the competitive landscape within the hematology and oncology sectors.

Oncopeptides AB Financial Statement Overview

Summary

Overall, Oncopeptides AB is facing financial challenges characterized by persistent losses, high leverage, and cash flow shortfalls. The company needs to improve operational efficiency and profitability to enhance financial stability. Strengths include a strong cash position and the ability to secure financing to sustain operations.

Income Statement

Oncopeptides AB has shown inconsistent revenue trends with significant fluctuations over the years. The company has consistently reported negative net income, indicating ongoing losses. Additionally, the high negative EBIT margin reflects operational inefficiencies or high operating costs relative to revenue.

Balance Sheet

The company's balance sheet shows a high level of liabilities compared to its equity, indicating a high debt-to-equity ratio. However, the company maintains a relatively strong cash position, which could help manage short-term liabilities. The equity ratio has deteriorated over time, suggesting decreasing asset financing through equity.

Cash Flow

Oncopeptides AB has consistently reported negative operating and free cash flows, highlighting cash burn issues. Despite this, the company has managed to secure financing to support operations. The free cash flow to net income ratio is negative, emphasizing the challenge in generating cash from its core operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
31.65M	35.22M	8.36M	118.30M	0.00
	Gross Profit
28.98M	36.30M	8.35M	65.17M	-14.40M
	EBIT
-283.50M	-253.45M	-349.35M	-1.42B	-1.59B
	EBITDA
-283.50M	-231.62M	-319.62M	-1.40B	-1.58B
	Net Income Common Stockholders
-284.61M	-249.11M	-337.95M	-1.43B	-1.59B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
178.54M	173.44M	344.51M	362.19M	840.25M
	Total Assets
244.19M	238.38M	385.32M	439.38M	946.76M
	Total Debt
121.89M	126.16M	9.54M	14.19M	19.36M
	Net Debt
-56.64M	-47.25M	-334.97M	-347.99M	-820.90M
	Total Liabilities
189.91M	181.60M	91.03M	228.51M	369.86M
	Stockholders Equity
54.28M	56.78M	294.29M	210.87M	576.90M
Cash Flow		Free Cash Flow
-260.57M	-279.61M	-423.02M	-1.52B	-1.31B
	Operating Cash Flow
-260.57M	-279.49M	-420.51M	-1.52B	-1.30B
	Investing Cash Flow
496.00K	-116.00K	-2.51M	-339.00K	-20.13M
	Financing Cash Flow
263.81M	106.89M	392.40M	1.03B	1.32B

Oncopeptides AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCO, the sentiment is Negative. The current price of 1.52 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.82, and below the 200-day MA of 1.76, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 28.62 is Positive, neither overbought nor oversold. The STOCH value of 4.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ONCO.

Oncopeptides AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
XBRANE	48 Neutral	kr379.37M	―	-47.73%	―	45.52%	93.35%
IMMU	44 Neutral	kr267.41M	―	-18.79%	―	―	21.85%
ONCO	40 Underperform	kr321.97M	―		―	1.72%	32.54%
ISOFOL	36 Underperform	kr185.74M	―	-54.29%	―	-100.00%	-17.35%
GUARD	32 Underperform	€375.12M	―	-205.65%	―	―	24.25%
CANTA	31 Underperform	kr289.38M	―	-167.55%	―	―	46.67%

Oncopeptides AB Corporate Events

Oncopeptides AB Annual General Meeting: Key Resolutions and Shareholder Program

Oncopeptides AB held its Annual General Meeting where key resolutions were passed, including the adoption of the annual report and the re-election of board members. A new long-term shareholder program was introduced, offering Restricted Share Units to board members, enhancing their stake in the company. The meeting also authorized the Board to issue new shares, warrants, and convertibles, aiming to increase financial flexibility and support potential acquisitions or project development. These decisions are poised to impact Oncopeptides’ operational strategy and shareholder engagement, potentially strengthening its market position.

Oncopeptides Initiates Real-World Study of Pepaxti in Spain

Oncopeptides AB has launched a new real-world evidence study in Spain to evaluate the use of its drug Pepaxti in routine clinical settings for patients with relapsed, refractory multiple myeloma. This study, named LAGOON, marks the first of its kind for Pepaxti in Spain and aims to collect data on the drug’s effectiveness and safety, supporting clinical decision-making and market development. The study’s findings will contribute to Oncopeptides’ efforts to provide relevant data to healthcare providers, payers, and regulators across Europe.

Oncopeptides AB Reports Strong Q1 2025 Growth and Strategic Advances

Oncopeptides AB reported a significant 161% increase in net sales in Q1 2025 compared to the previous year, driven by its expanded commercial footprint in Europe and strategic initiatives. The company secured its first orders in Italy following a positive reimbursement decision and is progressing with partnership negotiations in Japan. Additionally, the FDA lifted the clinical hold on its next-generation drug OPD5, opening new opportunities for market expansion in the U.S. These developments underscore Oncopeptides’ commitment to enhancing its market position and advancing its innovative pipeline.

Oncopeptides AB to Release Q1 2025 Financial Report

Oncopeptides AB announced the upcoming release of its Q1 2025 financial report, scheduled for May 15, 2025. The company will host a webcast and Q&A session for investors, analysts, and media, led by CEO Sofia Heigis and CFO Henrik Bergentoft. This event provides stakeholders an opportunity to gain insights into the company’s financial performance and strategic direction.